08:05 AM EDT, 06/24/2024 (MT Newswires) -- BioNTech (BNTX) and Duality Biologics said Monday that the US Food and Drug Administration has granted fast-track designation for their experimental drug, BNT324/DB-1311, to treat metastatic castration-resistant prostate cancer.
The designation, which facilitates the development and expedites the review of new drugs and vaccines, was based on preliminary safety and efficacy data from an ongoing phase 1/2 trial, the companies said.
Price: 86.40, Change: +1.76, Percent Change: +2.08